REFERENCES
- Jones P, Cannon M. The new epidemiology of schizophrenia. Psychiatric Clin N Am 1998; 21: 1–25, [CSA]
- Cannon M, Caspi A, Moffitt T E, et al. Evidence for early-childhood, pan developmental impairment specific to schizophrenia. Arch Gen Psychiatry 2002; 59: 449–56, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Akbarian S, Vinuela A, Kim J, Potkin S, Bunney W J, Jones E. Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch Gen Psychiatry 1993; 50: 178–87, [PUBMED], [INFOTRIEVE], [CSA]
- Akbarian S, Bunney W J, Potkin S, et al. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry 1993; 50: 169–77, [PUBMED], [INFOTRIEVE], [CSA]
- Harrison P J, Weinberger D R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005; 10: 40–68, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Davidson M, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z, Mark M. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry 1999; 156: 1328–35, [PUBMED], [INFOTRIEVE], [CSA]
- Torrey E F, Taylor E H, Bracha H S, et al. Prenatal origin of schizophrenia in a subgroup of discordant monozygotic twins. Schizophr Bull 1994; 20: 423–32, [PUBMED], [INFOTRIEVE], [CSA]
- Walker E, Savoie T, Davis D. Neuromotor precursors of schizophrenia. Schizophr Bull 1994; 20: 441–52, [PUBMED], [INFOTRIEVE], [CSA]
- Jones P B, Rantakallio P, Hartikainen A L. Schizophrenia as a long-term outcome of pregnancy, delivery and perinatal complications: a 28-year follow-up of the 1966 North Finland general population birth cohort. Am J Psychiatry 1998; 155: 355–64, [PUBMED], [INFOTRIEVE], [CSA]
- Eagles J M. Are polioviruses a cause of schizophrenia?. Br J Psychiatry 1992; 160: 598–600, [PUBMED], [INFOTRIEVE], [CSA]
- Susser E, Brown A, Klonowski E, Allen R, Lindenbaum J. Schizophrenia and impaired homocysteine metabolism: a possible association. Biol Psychiatry 1998; 44: 141–3, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Mortensen P R, Pedersen C B, Westergaard T, Wohlfahrt J, Ewald H, Mors O. Effects of family history and place and season of birth on the risk of schizophrenia. N Eng J Med 1999; 340: 603–8, [CSA], [CROSSREF]
- Brown A S, Hooton J, Schaefer C A, et al. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry 2004; 161: 889–95, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Gilmore J H, Fredrik Jarskog L, Vadlamudi S, Lauder J M. Prenatal infection and risk for schizophrenia: IL-1beta, IL-6, and TNFalpha inhibit cortical neuron dendrite development. Neuropsychopharmacology 2004; 29: 1221–9, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Gilmore J H, Jarskog L F, Vadlamudi S. Maternal infection regulates BDNF and NGF expression in fetal and neonatal brain and maternal-fetal unit of the rat. J Neuroimmunol 2003; 138: 49–55, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kim J J, Kwon J S, Park H J, et al. Functional disconnection between the prefrontal and parietal cortices during working memory processing in schizophrenia: a[15(O)]H2O PET study. Am J Psychiatry 2003; 160: 919–23, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Parikh V, Evans D R, Khan M M, Mahadik S P. Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. Schizophr Res 2003; 60: 117–23, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Szekeres G, Juhasz A, Rimanoczy A, Keri S, Janka Z. The C270T polymorphism of the brain-derived neurotrophic factor gene is associated with schizophrenia. Schizophr Res 2003; 65: 15–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Fanous A H, Neale M C, Straub R E, et al. Clinical features of psychotic disorders and polymorphisms in HT2A, DRD2, DRD4, SLC6A3 (DAT1), and BDNF: a family based association study. Am J Med Genet 2004; 125B: 69–78, [CSA], [CROSSREF]
- Miklic S, Juric D M, Caman-Krzan M. Differences in the regulation of BDNF and NGF synthesis in cultured neonatal rat astrocytes. Int J Eat Dev Neurosci 2004; 22: 119–30, [CSA], [CROSSREF]
- Bai O, Chlan-Fourney J, Bowen R, Keegan D, Li X M. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 2003; 71: 127–31, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Parikh V, Khan M M, Mahadik S P. Olanzapine counteracts reduction of brain-derived neurotrophic factor and TrkB receptors in rat hippocampus produced by haloperidol. Neurosci Lett 2004; 356: 135–9, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hong C J, Yu Y W, Lin C H, Tsai S J. An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients. Neurosci Lett 2003; 349: 206–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- O'Neill M J, Bleakman D, Zimmerman D M, Nisenbaum E S. AMPA receptor potentiators for the treatment of CNS disorders. Curr Drug Targets C NS Neurol Disord 2004; 3: 181–94, [CSA], [CROSSREF]
- Davis K, Kahn R, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148: 1474–86, [PUBMED], [INFOTRIEVE], [CSA]
- Goff D, Evins A. Negative symptoms in schizophrenia: neurobiological models and treatment response. Harv Rev Psychiatry 1998; 6: 59–77, [PUBMED], [INFOTRIEVE], [CSA]
- Hollerman J R, Abercrombie E D, Grace A A. Electrophysiological, biochemical, and behavioral studies of acute haloperidol-induced depolarization block of nigral dopamine neurons. Neuroscience 1992; 47: 589–601, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kapur S, Arenovich T, Agid O, Zipursky R, Lindborg S, Jones B. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry 2005; 162: 939–46, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Svensson T H, Mathe J M, Andersson J L, Nomikos G G, Hildebrand B E, Marcus M. Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoreceptor antagonism. J Clin Psychopharmacol 1995; 15: 11s–8s, [PUBMED], [INFOTRIEVE], [CSA]
- Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci 2000; 25: 161–6, [PUBMED], [INFOTRIEVE], [CSA]
- Grace A A, Bunney B S, Moore H, Todd C L. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci 1997; 20: 31–7, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med 1998; 42: 211–21, [PUBMED], [INFOTRIEVE], [CSA]
- Okubo Y, Suhara T, Suzuki K, et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997; 385: 634–6, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Laruelle M, Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol 1999; 13: 358–71, [PUBMED], [INFOTRIEVE], [CSA]
- Castner S A, Williams G V, Goldman-Rakic P S. Reversal of working memory deficits by short-term dopamine D1 receptor stimulation. Science 2000; 287: 2020–2, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Goldman-Rakic P S, Castner S A, Svensson T H, Siever L J, Williams G V. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) 2004; 174: 3–16, [CSA]
- Shifman S, Bronstein M, Sternfeld M, et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 2002; 71: 1296–302, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Egan M F, Goldberg T E, Kolachana B S, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 2001; 98: 6917–22, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Goff D C, Coyle J T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001; 158: 1367–77, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Krystal J H, Karper L P, Seibyl J P, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199–214, [PUBMED], [INFOTRIEVE], [CSA]
- Lahti A C, Koffel B, LaPorte D, Tamminga C A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995; 13: 9–19, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kegeles L S, Abi-Dargham A, Zea-Ponce Y, et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 2000; 48: 627–40, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Jentsch J, Roth R. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999; 20: 201–25, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Meador-Woodruff J H, Healy D J. Glutamate receptor expression in schizophrenic brain. Brain Res Reviews 2000; 31: 288–94, [CSA], [CROSSREF]
- Tsai G, Yang P, Chung L-C, Lange N, Coyle J. D-Serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998; 44: 1081–9, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Heresco-Levy U, Javitt D, Ermilov M, Mordel C, Silipo G, Lichenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999; 56: 29–36, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Heresco-Levy U. N-Methyl-D-aspartate (NMDA) receptor-based treatment approaches in schizophrenia: the first decade. Int J Eat Neuropsychopharmacol 2000; 3: 243–58, [CSA], [CROSSREF]
- Goff D C, Tsai G, Levitt J, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999; 56: 21–7, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Goff D, Henderson D, Evins A, Amico E. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 1999; 45: 512–4, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Goff D C, Hennen J, Tsai G, Evins A E, Yurgelun-Todd D, Renshaw P. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol Psychiatry 2002; 51: 493–7, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Breese G R, Knapp D J, Moy S S. Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness. Neurosci Biobehav Rev 2002; 26: 441–55, [PUBMED], [INFOTRIEVE], [CSA]
- Stefansson H, Sigurdsson E, Steinthorsdottir V, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002; 71: 877–92, [PUBMED], [INFOTRIEVE], [CSA]
- Chumakov I, Blumenfeld M, Guerassimenko O, et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci USA 2002; 99: 13675–80, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Egan M F, Straub R E, Goldberg T E, et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci USA 2004; 101: 12604–9, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Volk D W, Pierri J N, Fritschy J M, Auh S, Sampson A R, Lewis D A. Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb Cortex 2002; 12: 1063–70, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Lewis D A, Volk D W, Hashimoto T. Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology (Berl) 2004; 174: 143–50, [CSA]
- Kasai K, Shenton M E, Salisbury D F, et al. Progressive decrease of left superior temporal gyrus gray matter volume in patients with first-episode schizophrenia. Am J Psychiatry 2003; 160: 156–64, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kasai K, Shenton M E, Salisbury D F, et al. Progressive decrease of left Heschl gyrus and planum temporale gray matter volume in first-episode schizophrenia: a longitudinal magnetic resonance imaging study. Arch Gen Psychiatry 2003; 60: 766–75, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ho B C, Andreasen N C, Nopoulos P, Arndt S, Magnotta V, Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry 2003; 60: 585–94, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Lieberman J, Chakos M, Wu H, et al. Longitudinal study of brain morphology in first episode schizophrenia. Biol Psychiatry 2001; 49: 487–99, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Fuller R, Nopoulos P, Arndt S, O'Leary D, Ho B C, Andreasen N C. Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance. Am J Psychiatry 2002; 159: 1183–9, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hoff A, Faustman W, Weineke M, et al. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment refractory state hospital schizophrenic inpatients. Neuropsychopharmacology 1996; 15: 361–9, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Salisbury D F, Shenton M E, Griggs C B, Bonner-Jackson A, McCarley R W. Mismatch negativity in chronic schizophrenia and first-episode schizophrenia. Arch Gen Psychiatry 2002; 59: 686–94, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Norman R M, Malla A K. Duration of untreated psychosis: a critical examination of the concept and its importance. Psychol Med 2001; 31: 381–400, [PUBMED], [INFOTRIEVE], [CSA]
- Friis S, Larsen T K, Melle I, et al. Methodological pitfalls in early detection studies—the NAPE Lecture 2002. Nordic Association for Psychiatric Epidemiology. Acta Psychiatr Scand 2003; 107: 3–9, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Harrington S M, McGorry P D, Krstev H. Does treatment delay in first-episode psychosis really matter?. Psychol Med 2003; 2003: 97–110, [CSA]
- Tsai G, Goff D C, Chang R W, Flood J, Baer L, Coyle J T. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 1998; 9: 1207–13, [CSA]
- Lohr J B. Oxygen radicals and neuropsychiatric illness. Arch Gen Psychiatry 1991; 48: 1097–106, [PUBMED], [INFOTRIEVE], [CSA]
- Gunne L M, Andren P E. An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia. Clin Neuropharmacol 1993; 16: 90–5, [PUBMED], [INFOTRIEVE], [CSA]
- Waddington J L. Tardive dyskinesia in schizophrenia and other disorders: associations with ageing, cognitive dysfunction, and structural brain pathology in relation to neuroleptic exposure. Psychopharmacology 1987; 2: 11–22, [CSA]
- Sonkusare S K, Kaul C L, Ramarao P. Dementia of Alzheimer's disease and other neurodegenerative disorders—memantine, a new hope. Pharmacol Res 2005; 51: 1–17, [PUBMED], [INFOTRIEVE], [CSA]
- Olney J W, Farber N B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998–1007, [PUBMED], [INFOTRIEVE], [CSA]
- Rogawski M A, Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med 2004; 10: 685–92, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Morland C, Boldingh K A, Iversen E G, Hassel B. Valproate is neuroprotective against malonate toxicity in rat striatum: an association with augmentation of high-affinity glutamate uptake. J Cereb Blood Flow Metab 2004; 24: 1226–34, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kihara T, Sawada H, Nakamizo T, et al. Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity. Biochem Biophys Res Commun 2004; 325: 976–82, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Domercq M, Matute C. Neuroprotection by tetracyclines. Trends Pharmacol Sci 2004; 25: 609–12, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Adler LA J. R, Edson R, et al. Vitamin E treatment for tardive dyskinesia. Arch Gen Psychiatry 1999; 56: 836–41, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Cadet J L, Lohr J B. Possible involvement of free radicals in neuroleptic-induced movement disorders: evidence from treatment of tardive dyskinesia with vitamin E. Ann NY Acad Sci 1989; 570: 176–85, [PUBMED], [INFOTRIEVE], [CSA]
- Lohr J B, Cadet J L, Larson L, et al. Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms. Schizophr Bull 1988; 14: 291–6, [PUBMED], [INFOTRIEVE], [CSA]
- Shriqui C L, Bradwejn J, Annable L, Jones B D. Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study. Am J Psychiatry 1992; 149: 391–3, [PUBMED], [INFOTRIEVE], [CSA]